FTC Can't See Certain Docs In AbbVie Pay-For-Delay Row
A Georgia federal judge has allowed AbbVie, Actavis and other drugmakers facing pay-for-delay allegations involving patents for testosterone drug AndroGel to avoid disclosing most of a disputed set of documents to...To view the full article, register now.
Already a subscriber? Click here to view full article